

# Non-Preferred Oral Diclofenac Agents

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limits
Diclofenac potassium 25 mg tablets Zipsor (diclofenac potassium) 25 mg – brand and generic capsules Zorvolex (diclofenac sodium) 18 mg, 35 mg – brand and branded generic capsules	May be subject to quantity limit

## **APPROVAL CRITERIA**

Requests for non-preferred oral diclofenac single ingredient products (Diclofenac potassium 25 mg tablets, Zipsor 25 mg – brand and generic capsules, Zorvolex 18 mg, 35 mg – brand and branded generic capsules) may be approved if the following criteria is met:

- I. Individual has had a trial of and inadequate response or intolerance to two preferred single oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), one of which must be a generic diclofenac potassium 50 mg tablets or generic diclofenac sodium tablets; **AND**

Preferred Agents: Generic prescription oral NSAIDs;

**AND**

- II. Documentation is provided for why the requested oral diclofenac is clinically necessary;

**OR**

- III. Individual is requesting Zipsor 25 mg brand or generic capsules and meets the following criteria:
  - A. Individual is age 12 to 17; **AND**
  - B. Documentation is provided that individual has had a trial and inadequate response or intolerance to one preferred oral generic prescription non-steroidal anti-inflammatory drugs (NSAIDs). Medication samples/coupons/discount cards are excluded from consideration as a trial.

## **Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2021. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: April 13, 2021.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.

5. Derry S, Conaghan P, Da Silva JA, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev*. 2016 Apr 22; 4: CD007400.
6. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care Res* 2020 pp1-14. Available at: <https://www.rheumatology.org/Portals/0/Files/Osteoarthritis-Guideline-Early-View-2019.pdf>
7. Lanza FL, Chan FKI, Quigley EMM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for Prevention of NSAID-Related Ulcer Complications. *Am J Gastroenterol*. 2009; 104:728 – 738.**doi: 10.1038/ajg.2009.115**. Available from: <http://s3.gi.org/physicians/guidelines/NSAIDJournalPublicationFebruary2009.pdf>.
8. The NCCN Drugs & Biologics Compendium (NCCN Compendium™)© 2020 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.